Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials.
Shankar
Lalitha K
LK
Cancer Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. shankarl@mail.nih.gov
Hoffman
John M
JM
Bacharach
Steve
S
Graham
Michael M
MM
Karp
Joel
J
Lammertsma
Adriaan A
AA
Larson
Steven
S
Mankoff
David A
DA
Siegel
Barry A
BA
Van den Abbeele
Annick
A
Yap
Jeffrey
J
Sullivan
Daniel
D
D002986:Clinical Trials as Topic / Q000592:standards*; D019788:Fluorodeoxyglucose F18; D006801:Humans; D009316:National Institutes of Health (U.S.); D009369:Neoplasms / Q000000981:diagnostic imaging* / Q000628:therapy*; D017063:Outcome Assessment, Health Care / Q000379:methods* / Q000592:standards*; D049268:Positron-Emission Tomography / Q000379:methods / Q000592:standards*; D011379:Prognosis; D019275:Radiopharmaceuticals; D016896:Treatment Outcome; D014481:United States
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18